logic efficacy of hydroxyurea. Further investigation may uncover other mediators of hydroxyurea PK.
The authors recommend pharmacogenetic (PGx) analysis of OATP1B transporter and other transporter mutations and polymorphisms. Single nucleotide polymorphisms that impact function of OAT1B transporters have previously been described (5, 10) . Identification of PGx predictors of hydroxyurea PK and pharmacodynamics could eventually lead to dose prediction models and personalized prescription.
Hydroxyurea therapy is already personalized in terms of individualizing the maximum tolerated dose (MTD) based on hematologic and clinical response and sharing response information (hemoglobin, hemoglobin F, and mean corpuscular volume and blood smear findings) with the patient. PK and PGx-based dosing models have the potential to further improve clinical care by allowing patients to achieve MTD through personalized dosing rather than with weight-based dosing. This could reduce the time to reach MTD and minimize family and clinician burden related to frequent monitoring every 2-4 weeks. This information could also define those patients who fail to respond owing to poor adherence versus those whose PK dictate a higher dose.
In summary, results are consistent with the previously demonstrated impact of cell membrane transporters in PK variation of xenobiotics. Ongoing studies in the field of cell membrane transporters such as OATP1B may lead to precision care for individuals with SCA and other acute and chronic medical conditions. 
